AKTS - Aktis Oncology • Market Cap
Aktis Oncology, Inc. is a clinical-stage biotechnology company dedicated to transforming the treatment of solid tumors through the development of targeted alpha-emitting radiopharmaceuticals. The company's innovative approach leverages its proprietary platform to create highly potent and selective radioligand therapies designed to deliver alpha radiation directly to cancer cells, minimizing damage to healthy tissues. Aktis Oncology's pipeline is focused on addressing significant unmet needs in oncology, particularly for patients with difficult-to-treat solid tumors. Their lead programs are engineered to target specific tumor antigens, ensuring precise delivery of therapeutic payloads. By utilizing alpha emitters, which have a short path length and high linear energy transfer, Aktis aims to achieve superior tumor killing efficacy compared to traditional beta-emitting radiopharmaceuticals. The company's strategy involves advancing its lead candidates through clinical development, while also expanding its platform to discover new targets and develop next-generation radiopharmaceuticals. Aktis Oncology is positioned within the rapidly evolving field of radiopharmaceutical therapy, seeking to establish itself as a leader in this promising modality for cancer treatment.
837,6M
Market Cap
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
331,5M
EV
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
33
EV/Revenue
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
-3,9
EV/EBITDA
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
-3,8
EV/EBIT
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!